Immune balance, restored
At ThyTech, we are developing off-the-shelf regulatory T cell therapies for patients whose immune system is out of balance
Immune balance, restored
Off-the-shelf regulatory T-cell therapies for patients with serious immunological and inflammatory disorders.
Immune balance, restored
Off-the-shelf regulatory T-cell therapies for patients with serious immunological and inflammatory disorders.
Immune balance, restored
At ThyTech, we are developing off-the-shelf regulatory T-cell therapies for patients with serious diseases caused by immune dysregulation
Straight from the source
Our first-in-class thyTreg™ therapies use regulatory T cells purified from their natural source, the thymus gland.
These thyTreg cells are outstanding candidates for the treatment and prevention of serious imbalances of the immune system that underly many acute and chronic conditions and diseases.
First in the clinic
We are excited by the positive preliminary outcomes seen in our first thyTreg clinical trial, in which we aim to prevent graft rejection in heart transplant infants by thyTreg cells from their own thymic tissue.
Off the shelf
Next, we plan to demonstrate the allogeneic potential of thyTreg cells, which may evade recognition by the patient’s immune system, in a clinical trial in COVID patients experiencing life-threatening immune hyperactivation.
By combining allogeneic thyTreg sourcing with large-scale manufacturing, our products can be available off-the-shelf, thereby improving patient access.
Straight from the source
Our first-in-class thyTreg™ therapies use regulatory T cells purified from their natural source, the thymus gland.
These thyTreg cells are outstanding candidates for the treatment and prevention of serious imbalances of the immune system that underly many acute and chronic conditions and diseases.
First in the clinic
We are excited by the positive preliminary outcomes seen in our first thyTreg clinical trial, in which we aim to prevent graft rejection in heart transplant infants by thyTreg cells from their own thymic tissue.
Off the shelf
Next, we plan to demonstrate the allogeneic potential of thyTreg cells, which may evade recognition by the patient’s immune system, in a clinical trial in COVID patients experiencing life-threatening immune hyperactivation.
By combining allogeneic thyTreg sourcing with large-scale manufacturing, our products can be available off-the-shelf, thereby improving patient access.
Endless possibilities
As a spin-off from the “Gregorio Marañón” Health Research Institute in Madrid, we are committed to applying our expertise in immune regulation to the real challenges experienced by our patients.
From transplant rejection to autoimmune diseases, and from severe inflammation to neurodegenerative disorders, the possibilities for an effective off-the-shelf thyTreg therapy are endless.
Endless possibilities
As a spin-off from the “Gregorio Marañón” Health Research Institute in Madrid, we are committed to applying our expertise in immune regulation to the real challenges experienced by our patients.
From transplant rejection to autoimmune diseases, and from severe inflammation to neurodegenerative disorders, the possibilities for an effective off-the-shelf thyTreg therapy are endless.
Original T cell image by Blausen Medical, adapted here from Wikimedia Commons
© 2024 Thytech | All Rights Reserved | Powered by Scienseed
Original T cell image by Blausen Medical, adapted here from Wikimedia Commons
© 2024 Thytech | All Rights Reserved | Powered by Scienseed